MAP2K1 and breast carcinoma: However, MEK1 activation and subsequent phosphorylation of the MAPKs is associated with a poor response to antihormonal therapy and decreased patient survival in clinical breast cancer [27,28], and a recent study determined that blockade of MAPK affects co-repressor recruitment and potentiates 4-OHT action [29].